Free Trial!
Today’s Best Stocks To Trade! Click Here
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.
QUOTEMEDIA INC. (OTCBB: QMCI)
Detailed Quote: http://www.otcpicks.com/quotes/QMCI.php
Company Profile: http://www.otcpicks.com/quotemedia/quotemedia.htm
QuoteMedia, Inc. is a leading software developer and provider of real-time streaming financial market information, decision-support, news and research solutions to brokerage, financial services companies, business and media corporations. Among its many leading-edge products lines, the Company offers data feeds, news, dynamic market content solutions, interactive stock research tools, financial applications and real-time wireless applications. QuoteMedia provides data and services for companies such as the NASDAQ, the OTCBB, Dow Jones & Company, Forbes.com, Scotia Capital, Business Wire, Southwest Securities, Regal Securities, FBR Direct, Broadridge Financial Solutions, Inc., AIM Trimark, Zacks Investment Research, ChoiceTrade, QTrade, Schaeffer's Investment Research, Automated Financial Systems, WallStreet*E, and others. For more information, visit www.quotemedia.com.
QMCI News:
June 6 - QuoteMedia to Exhibit at SIFMA Technology Management Conference in New York, June 10 - 12
QuoteMedia, Inc. (OTCBB: QMCI), a leading provider of market data, corporate research information and financial applications, announced that it is scheduled to participate as an exhibitor at the Securities Industry and Financial Markets Association's Technology Management Conference and Exhibit in New York, taking place on June 10th through 12, 2008.
SIFMA's 28th Annual Technology Management Conference & Exhibit is the industry's leading event with over 300 vendors and 7,000 attendees, and it will allow QuoteMedia to present its products and services to the senior executives responsible for managing communications, data processing, market data, information security, trading room support, web and Internet technology, information systems and other related technology activities.
In particular, QuoteMedia will be demonstrating its newly launched QuotestreamTM Professional streaming portfolio management system, together with its QuotestreamTM Wireless companion product, designed for use by financial services professionals. QuotestreamTM Professional offers unparalleled functionality at extremely aggressive pricing at a time when cost reduction, with no reduction in capabilities, is a paramount concern across the industry.
QuoteMedia will also be showcasing QuotestreamTM II for enterprise level deployments to retail customers. QuotestreamTM II is geared towards providing a professional level experience to non-professional users.
Additionally, QuoteMedia will be available to meet with potential clients regarding comprehensive content solutions for intranet and public facing websites and media/web portals.
Finally, sales and technical staff will be on hand to discuss QuoteMedia's broad range of DataFeed solutions for companies looking to power their applications and systems with ultra-low latency streaming quote data and supplementary feeds, or those wishing to replace existing legacy solutions with state-of-the-art data services, while benefiting from significant cost savings.
Paul Pryde, QuoteMedia's Senior Vice President & Regional Director, together with New York Corporate Sales Director George Katsch, and Chief Technology Officer Christian Amott, will be present to meet attendees at Booth #1608.
The conference will take place at the Hilton New York, 1335 Avenue of the Americas, NYC. For more information on the event, visit http://events.sifma.org/2008/107/event.aspx?id=526.
GOLDSPRING INCORPORATED (OTCBB: GSPG | Quote | Chart | News | PowerRating) "Up 54.59% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/GSPG.php
GoldSpring, Inc. is a North American precious metals mining company, focused in Nevada, with extensive, contiguous property in the Comstock Lode District. Our Company was formed in mid-2003, and we acquired two properties in the Comstock Lode before the end of the year. We secured permits, built an infrastructure and brought the exploration project into test mining production within a year of its acquisition. The Company, in 2005, began consolidating the Comstock Lode by acquiring additional properties in the district, expanding our footprint and creating opportunities for exploration and mining. We are an emerging company, looking to build on our success through the acquisition of other mineral properties in the Comstock Lode District with reserves or exploration potential. The Company's objectives are to increase reserves through exploration, expand its footprint in the Comstock, resume mining, optimize its production and maximize shareholder value.
GSPG News:
June 6 - GoldSpring to Provide Special Investor Update on Tuesday, June 10th to Discuss Significant Developments and Preliminary Findings of 43-101 Resource Report on Valuation of Company's Mineral Holdings in Nevada's Comstock Lode Mining District
Company To Hold Conference Call and Webcast at 11 a.m. Eastern Time that Day
GoldSpring, Inc. (OTCBB: GSPG), the largest mineral rights land position in Nevada's Comstock Lode Mining District, announced that it will hold a conference call on Tuesday, June 10th at 11 a.m. eastern time at which time it expects to discuss the preliminary findings of the 43-101 resource report that was conducted by an independent geology firm to determine the value of the mineral rights held by the Company in Nevada's Comstock Lode Mining District.
For the conference call, interested participants should dial 866-214-7077 when calling within the United States or 416-915-9608 when calling internationally along with pass code 8254829. There will be a playback available as well. To listen to the playback, please call 888-203-1112 when calling within the United States or 719-457-0820 when calling internationally. Please use pass code 8254829 for the replay.
The call is also being webcast and can be access at GoldSpring's website at www.goldspring.us.
Pursuant to Regulation FD, the company reports that drill hole #40, which is not included in the preliminary resource report being discussed on Tuesday, encountered 5 feet of ore containing 1.937 ounces of gold per ton. This is the highest grade of ore since the commencement of the drilling program in December 2007.
COST PLUS INCORPORATED (NASD: CPWM | Quote | Chart | News | PowerRating) "Up 21.31% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CPWM.php
Cost Plus, Inc., along with its subsidiaries, operates as a specialty retailer of casual home furnishings and entertaining products in the United States. It offers home decorating items, such as furniture, rugs, pillows, bath linens, lamps, window coverings, frames, and baskets; and furniture products, including ready-to-assemble living and dining room pieces, handcrafted case goods, and occasional pieces. The company also provides kitchen items, including glassware, ceramics, textiles, and cooking utensils; and kitchen products comprising baking, food preparation, barbecue, and dining. In addition, it provides jewelry, fashion accessories, and personal care items, as well as gift and decorative accessories, including collectibles, candles, framed art, and holiday and seasonal items. Further, the company offers gourmet foods and beverages, including wine, microbrewed and imported beer, coffee, tea, and bottled water. As of December 31, 2007, it operated 298 stores under World Market, Cost Plus World Market, Cost Plus Imports, and World Market Stores names in 34 states. The company was founded in 1946 and is headquartered in Oakland, California.
CPWM News:
June 9 - Cost Plus Comments on Pier 1 Proposal
Cost Plus, Inc. (NASD: CPWM | Quote | Chart | News | PowerRating) confirmed that it received a non-binding, highly conditional proposal from Pier 1 Imports, Inc. (NYSE: PIR) to acquire 100% of the outstanding shares of Cost Plus in a stock-for-stock transaction.
The Cost Plus Board of Directors, consistent with its fiduciary duties and in consultation with its financial and legal advisors, will meet in due course to review and discuss Pier 1's unsolicited proposal. The Company noted that Cost Plus shareholders do not need to take any action with regards to this proposal.
Peter J. Solomon Company is acting as financial advisor to Cost Plus and Skadden, Arps, Slate, Meagher & Flom LLP and Wilson, Sonsini, Goodrich & Rosati LLP are acting as legal advisors.
HOLLIS-EDEN PHARMACEUTICALS INCORPORATED (NASD: HEPH | Quote | Chart | News | PowerRating) "Up 9.28% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/HEPH.php
Hollis-Eden Pharmaceuticals, Inc. engages in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. The company, through its Hormonal Signaling Technology Platform, is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body's most abundant circulating adrenal steroid. These steroid hormones are designed to restore the biological activity of cellular signaling pathways disrupted by disease and aging, which regulate innate and adaptive immunity, reduce nonproductive inflammation, and stimulate cell proliferation. Its clinical drug development candidates include TRIOLEX (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and being prepared for clinical trials in rheumatoid arthritis; and APOPTONE (HE3235), a next-generation compound being prepared for clinical trials in cancer. In addition, Hollis-Eden has an active research program that is generating additional new clinical leads that are being evaluated in preclinical models of various diseases. The company was founded in 1992 and is headquartered in San Diego, California.
HEPH News:
June 9 - Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX(TM) Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes
Data to date demonstrate that TRIOLEX is safe and well tolerated, and improves insulin sensitivity and lowers fasting glucose levels in obese insulin resistant subjects
Hollis-Eden Pharmaceuticals, Inc. (NASD: HEPH | Quote | Chart | News | PowerRating) announced additional positive interim data from its on-going Phase I/II clinical trial with its investigational oral drug candidate TRIOLEX (HE3286), supporting the potential benefit of a novel anti-inflammatory approach to improving insulin sensitivity in patients with type 2 diabetes. The additional data extend previously reported data from this study and demonstrate that TRIOLEX is safe and well tolerated to date, and that it significantly improved insulin sensitivity and significantly lowered fasting blood glucose, insulin and triglyceride levels in obese insulin resistant subjects treated orally with the compound for 28 days when compared to placebo-treated subjects.
In addition, all subjects had elevated levels of MCP-1, a chemokine identified in the scientific literature to be associated with the cause of insulin resistance, before initiating TRIOLEX therapy, and showed a significant drop in MCP-1 in serum and IL-6 in peripheral blood mononuclear cells when treated with the compound at the highest dose, compared to placebo-treated subjects. This finding is consistent with the anti-inflammatory mechanism of action of TRIOLEX. The primary clinical investigator, Sherwyn Schwartz, M.D., CEO and Chief Medical Officer of dgd Research, Inc., in San Antonio, Texas, presented this additional data from the clinical trial yesterday at a corporate symposium held in conjunction with the 68th Scientific Sessions of the American Diabetes Association being held in San Francisco, California, from June 6th to 10th.
"What is most encouraging about the data," stated Dr. Schwartz, "is the observation that the TRIOLEX-treated subjects with the most impaired insulin resistance and higher levels of both insulin and fasting blood glucose had the largest improvement in these parameters. These data are intriguing because, in these subjects, the compound appeared to bring these parameters back to a normal range, which is important for safety concerns. To date there have been no reported incidence of hypoglycemia or any drug related serious adverse events. In addition, macrophage-induced inflammation in obese individuals is known to play an important role in causing insulin resistance. To see statistically significant reductions of MCP-1 in the serum and of IL-6 in cells of subjects treated with TRIOLEX versus subjects treated with placebo suggests the compound may be working through a novel pathway. The data demonstrating improvement in insulin sensitivity and glucose tolerance bode well for the potential of seeing a reduction in the clinical endpoint hemoglobin A1-c (HbA1-c) in a Phase II trial with TRIOLEX in patients with type 2 diabetes."
Summary of Data Presented
The 28-day double-blind placebo controlled clinical trial was designed to study the safety, tolerability, pharmacokinetics and potential activity of TRIOLEX at three dose levels when administered orally (5mg once daily, 5mg twice daily and 10mg twice daily) to obese insulin resistant subjects. Data presented yesterday were from 31 subjects who participated in the clinical trial. The Company reported no serious adverse events or systemic toxicity to date from TRIOLEX in all treated subjects, and all adverse events reported were mild and required no treatment. A total of 17 subjects were evaluated for improvement in insulin sensitivity as measured by a physiological index of glucose disposal (M-value) under euglycemic/hyperinsulinemic clamp conditions, a method widely used to assess whole body glucose metabolism and to test compounds for the treatment of type 2 diabetes.
The data presented showed that pre-diabetic, insulin resistant subjects treated with TRIOLEX exhibited a statistically significant increase in the "M" value (p < 0.018), indicating that they became more sensitive or responsive to insulin. The magnitude of the effect seen with TRIOLEX was a 32.8% increase. This compares favorably to a meta-analysis of the effect of the glitazones in 23 studies of type 2 diabetics with a 34% increase in M value. The effect of TRIOLEX on M value was found to be linearly correlated with the magnitude of insulin resistance at baseline, before treatment (p = 0.015). Although these subjects are not considered hyperglycemic or diabetic, their fasting plasma glucose levels are nevertheless above the normal range (>100 mg/dL). Treatment with TRIOLEX was associated with a reduction in both fasting blood glucose and insulin, restoring these to normal levels without causing hypoglycemia. As in the case of the improved insulin sensitivity, these effects exhibited a highly significant linear correlation with respect to their initial blood glucose (p = 0.002) and insulin levels (p < 0.001) at baseline. In a similar fashion, a triglyceride lowering effect was observed, which correlated linearly with the degree of triglyceride elevation at baseline, before treatment began (p = 0.037). These observations suggest that the potential therapeutic benefit of TRIOLEX to abrogate insulin resistance occurs as a function of the magnitude of dysregulation of glucose homeostasis, as reflected by the extent of fasting hyperglycemia and hyperinsulinemia.
In addition to these findings, treatment with TRIOLEX at the highest dose caused a significant reduction by day 14 in serum levels of the chemokine MCP-1 (p = 0.035). MCP-1 is one of the major effectors of inflammation that mediates excessive infiltration of macrophages in adipose tissue and other insulin-sensitive tissues in obese subjects, leading to insulin resistance. It has now been demonstrated that many of these inflammatory molecules not only participate in a feed-forward cycle of "low grade" chronic inflammation, but they directly interfere with insulin signaling during obesity, thereby providing an explanation for the involvement of inflammation in insulin resistance and type 2 diabetes. Moreover, peripheral blood mononuclear cells obtained from patients treated with TRIOLEX at the highest dose exhibited markedly diminished responses by day 14 (p = 0.024) to a pro-inflammatory stimulus that normally induces a high level of IL-6 secretion, which is clearly conserved in patients treated with placebo in the same trial. Taken together, these observations suggest that the anti-inflammatory properties of TRIOLEX translate into improved insulin sensitivity in humans, thus ameliorating insulin resistance. The Company is now initiating a follow-on Phase II clinical trial to demonstrate efficacy in long-term glycemic control in type 2 diabetic patients by assessment of HbA1-c levels, an approvable end-point for diabetes.
Additional Symposium Highlights
In addition to the data presented by Dr. Schwartz at the symposium, Giovanni Solinas, Ph.D., Laboratory of Metabolic Stress Biology, Division of Physiology, Dept. of Medicine, University of Fribourg, Switzerland, highlighted the role of obesity-induced inflammation in causing insulin resistance. Dr. Solinas was the lead author of several publications linking obesity-induced inflammation to insulin resistance. Along with his own work, Dr. Solinas' presentation included the work of several leading academic researchers who have reported that the chronic stimulation of the inflammatory kinases JNK and IKK can impair insulin signaling by inhibiting the biological function of IRS-1, a protein that acts as a major mediator of insulin action in target cells. This inflammatory pathway that leads to insulin resistance is well characterized in the scientific literature. In addition, activation of NF-kappaB due to inflammatory mediators or oxidative stress leads to a feed forward cycle of increased production of inflammatory cytokines such as MCP-1, TNF-alpha, IL-6 and IL-1beta.
William Cefalu, M.D., Professor and Chief, Division of Nutrition and Chronic Diseases, Pennington Biomedical Research Center, Louisiana State University System, highlighted the need for novel insulin sensitizers. He reviewed the current class of insulin sensitizers, known as PPAR-gamma agonists, and their efficacy and safety profile to date. He then described the potential mechanism of action of TRIOLEX and the differences between the glitazone class of insulin sensitizers and TRIOLEX. He pointed out that TRIOLEX acts independently of the PPAR-gamma pathway and thereby may avoid the side effects associated with the current glitazone class of insulin sensitizing agents, such as Avandia and Actos , which work through the PPAR-gamma pathway. Side effects reported to date with the glitazone class of drugs include weight gain, edema and increased cardiovascular events. To date, experiments in vitro have shown no evidence that TRIOLEX directly binds and/or transactivates the PPAR-gamma receptor. Unlike the glitazones, TRIOLEX does not cause body weight gain when administered to mice or rats. These and other observations are consistent with the Company's finding that TRIOLEX works through a pathway independent of the PPAR-gamma receptor. TRIOLEX is a pharmaceutically optimized version of one of the body's natural occurring ligands whose key function may be to restore immunological and metabolic homeostasis.
Richard Hollis, Chairman and CEO of Hollis-Eden, added, "We are honored to hold this symposium to assist the field of diabetes by advancing awareness of the latest research further establishing the role of inflammation as a culprit in insulin resistance. Furthermore, we are excited to share our clinical data supporting the potential role of our drug candidate TRIOLEX in addressing inflammation as an underlying cause of type 2 diabetes. While the primary focus of the study was safety and blood levels of TRIOLEX, by designing the study as we did, we were also able to show statistically significant signs of efficacy in improving insulin sensitivity, lowering fasting blood glucose levels, and lowering triglycerides, which is very exciting considering the limited treatment duration of only 28 days. These data, coupled with a significant reduction in levels of the inflammatory mediators MCP-1 and IL-6, further support our anti-inflammatory approach to improving insulin sensitivity and demonstrate the potential of TRIOLEX as an innovative, novel therapy for type-2 diabetes. Based on the consistently positive findings in our preclinical models of metabolic and inflammatory disorders, and our initial data in human clinical trials, we are now focused on accelerating our TRIOLEX development programs in type-2 diabetes, rheumatoid arthritis and inflammatory bowel disease (ulcerative colitis). Assuming successful clinical development and marketing approval by the FDA, we believe TRIOLEX represents a potential breakthrough therapy for metabolic disorders and inflammatory diseases that could be a first-in-line therapy with distinct competitive advantages in the marketplace relative to currently available treatments."
Type 2 Diabetes Market
There are approximately 20 million Americans and over 160 million people worldwide with type 2 diabetes. As a result of an aging population and a rise in obesity rates, a common risk factor in this disease, the prevalence of type 2 diabetes is increasing rapidly. Included among the therapeutic approaches to type 2 diabetes are drugs designed to increase insulin production by the pancreas, drugs to reduce glucose production by the liver, and drugs to increase the body's sensitivity to insulin, thereby improving glucose disposal by the blood stream. The global annual sales of oral anti-diabetic drugs exceed $11 billion annually. Of these insulin sensitizers, Avandia and Actos represent the largest class of oral anti-diabetic agents, currently garnering over $5 billion in worldwide sales annually. However, patient control of glucose levels remains a large unmet medical need as 64% of this patient population fails to achieve optimal glucose levels. Furthermore, now that it is increasingly understood that inflammation is at the root cause of insulin resistance, there is a need to address inflammation in type-2 diabetes.
MYECHECK INCORPORATED (OTCBB: MYEC | Quote | Chart | News | PowerRating) "Up 14.79% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MYEC.php
MyECheck, Inc., an early stage company, operates in the payment processing industry. It offers various solutions, such as real-time check authorization, payment guarantee, check image creation, and clearing and online reporting. The company's services include Remotely Created Check (RCC) Service, a payment engine that enables Internet merchants and other companies to accept payments online or over a telephone; and Check Authorization Service, which enables merchants to verify consumer provided data, check the status of the customer's bank account, provide evidence that the consumer has authorized the check, and predict the likelihood of a check being returned unpaid. Its services also include remote deposit capture and remittance processing solutions that enable companies to scan paper checks at the brick and mortar point of sale or back office, and remit check images for processing; merchant reporting services, including transaction history, and fees and settlement statements reports; and check guarantee services. In addition, the company offers services to support its RCC service, including fraud loss prevention services; and check remittance processing and remote deposit capture services for brick and mortar companies, such as banks and retailers. It provides electronic check image services to merchants, payment services providers, banks, and other businesses. The company was founded in 2004 and is based in El Dorado Hills, California.
MYEC News:
June 9 - MyECheck Inc. Announces Over 100% Growth in Revenues in First Two Months of Second Quarter 2008
Electronic Transaction Processor Also Posts April to May Revenue Growth at Over 60%
MyECheck Inc. (OTCBB: MYEC), an electronic transaction processor and provider of alternative payment solutions, announced that, in the first two months of the second quarter of 2008, unaudited revenues have exceeded the first quarter of 2008 by over 100%.
Furthermore, the company's unaudited revenues have increased by over 60% for the period May 2008 compared to April 2008.
The company noted that while there has been an economic downturn of late, the numbers would seem to point to a turn-around when it comes to online retailing. According to a recent report by eMarketer, "although consumers are reacting to the economic downturn by spending less, this will create more of a hardship for retail stores than for online retail outlets."
eMarketer estimates that US retail e-commerce sales (excluding travel) will reach $146 billion in 2008, up 14.3% over 2007.
And, according to Barrington Research, the 16-Stock group of electronic-transaction processors recorded its second consecutive month of positive price performance with a mean return of 4.47%. Twelve of the 16 stocks registered positive returns for the month, ranging from 2.8% for Western Union to 18.9% for Cardtronics. Besides Cardtronics, leading price performers for the month included Heartland Payments at 17.9%, Global Cash at 15.7% and Fidelity National 11.7%. The mean group return of 4.47% in May was greater than both the S&P 500 Index and the Dow Jones Industrial Average at 1% and minus-1.4%, respectively.
Ed Starrs, CEO of MyECheck, commented, "Our growth in this period is unprecedented for the company, and we expect that we will continue to increase our revenues as more of our customers are added."
The company notes that the numbers contained in this release are unaudited, and are made in good faith and based on all the financial information available to the company today.
MyECheck also wishes to caution readers that any forward looking statements are just beliefs or predictions, and that actual results might differ materially from those projected in any or all of the forward-looking statements. Further, past financial business, operations and stock performance are not necessarily indicative of the company's future performance.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com receives Internet data services from QuoteMedia (QMCI) in return for coverage on our site. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
